SNY Articles, Sanofi - From 12/27/23

First Wave BioPharma, Inc. (NASDAQ: FWBI) shares are skyrocketing Wednesday after the company entered a non-binding term sheet to sell its Nic...

MeiraGTx Holdings plc (NASDAQ: MGTX) on Thursday announced an asset purchase agreement with Janssen Pharmaceuticals Inc, a Johnson&n...

Sanofi SA (NASDAQ: SNY) is discontinuing the global clinical development program of tusamitamab ravtansine.  The decision is ba...

First Wave BioPharma Inc (NASDAQ: FWBI) has signed a non-binding term sheet to acquire ImmunogenX in an all-stock transaction with the combine...

Sanofi SA (NASDAQ: SNY), DNDi, and the HAT-r-ACC consortium announce that the European Medicines Agency’s (EMA) Committee for ...

Sanofi SA (NASDAQ: SNY) said it is terminating the licensing agreement for Maze Therapeutics Inc.'s treatment for a rare genetic...

Vanda Pharmaceuticals Inc (NASDAQ: VNDA) has acquired U.S. and Canadian rights to Ponvory (ponesimod) from Actelion Pharmaceuticals Ltd, ...

Sanofi SA (NASDAQ: SNY) says it has 12 drugs in development with a blockbuster potential (to make over $1 billion in annual sales), ...

IGM Biosciences Inc (NASDAQ: IGMS) said it will focus on two strategic areas: treating colorectal cancer using IgM death receptor 5 (DR5) agon...

Merck KGaA (OTC: MKGAF) (OTC: MKKGY) says its two Phase 3 EVOLUTION trials (evolutionRMS 1 and evolutionRMS 2) of evobruti...